Gilead

4Q Revenues:$7.3 billion (-14%)

4Q Earnings:$3.1 billion (-34%)

FY Revenues:$30.4 billion (-7%)

FY Earnings:$13.5 billion (-25%)

Comments: Harvoni sales were down 34% to $9.1 billion for the year, and Solvaldi sales were $4.0 billion, down 10% due to lower sales and competition, partially offset by sales of Epclusa (sofosbuvir and velpatasvir), which was launched in 2016, with sales of $1.8 billion for the year. Truvada sales were $3.6 billion, up 3%. Atripla sales were $2.6 billion, down 17%. Stribild sales were $1.9 billion, down 5%. Newly launched Genvoya, a 4-in-1 HIV regimen, had sales of $1.5 billion.